COMPANY PROFILE

PineTree Therapeutics

Explore full profile

Develops targeted protein degraders for drug-resistant cancers and other diseases

Cambridge, United StatesFounded 2019Biotech & Life Sciences

Valuation $250–500M Last recorded · 2025

Headcount <100 Current team size

Total funding $50–100M Disclosed equity funding

Unlock exact values

About PineTree Therapeutics

PineTree Therapeutics is a Cambridge, Massachusetts-based biotechnology company developing targeted protein degraders for oncology, with applications in inflammation and immunology. Its proprietary AbReptor™ platform is designed to selectively degrade membrane-bound and extracellular proteins, including disease-driving receptor tyrosine kinases associated with tumour growth and treatment resistance. The company is advancing modular bispecific and multispecific degraders, trispecific programmes and degrader–antibody-drug-conjugate approaches through preclinical development, with the goal of progressing lead programmes into clinical studies. PineTree also pursues strategic partnerships and licensing collaborations to develop new therapeutic applications.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2019
Headquarters: Cambridge, United States
Employees: 39
Open positions: 6
Dealroom signal: 86.1/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

3 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES BOther financing	Oct 2025	$47M	$188M	Korea Investment Partners · SGI Venture Capital · SV Investment · SJ Investment Partners	↗
SERIES AOther financing	Jul 2024	$17M	$118M	Schmidt · S&S Investment · DSC Investment · Stic Investment	↗

Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

PineTree Therapeutics website traffic

Latest recorded traffic for PineTree Therapeutics is 2.6K monthly website visits, up 116.7% over the last three months. PineTree Therapeutics's team grew 0% over the past year.

Latest monthly visits2.6K 3-month web change+116.7% 1-year team growth0%

Monthly website visitsNov 2022–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Open positions

Openings linked to this company in Dealroom

Administrative Coordinator (Part-Time, On-site)Cambridge, MA · Human Resources · Aug 23, 2026 Recruiting Experienced Chief Technology Officer Pinetree Therapeutics 26.07.28Cambridge, Massachusetts, United States, Northern America, Americas · C-Level · Aug 20, 2026 Recruiting Experienced Director / Sr. Director, Nonclinical Toxicology & PK (Remote/Hybrid) Pinetree therapeutics 26.11.05Cambridge, Massachusetts, United States, Northern America, Americas · Other · Aug 6, 2026 Chief Technology OfficerCambridge, Massachusetts, United States, Northern America, Americas · C-Level · Jul 31, 2026 Director / Sr. Director, Nonclinical Toxicology & PKCambridge, Massachusetts, United States, Northern America, Americas · Other · Jul 24, 2026 Director of Business DevelopmentCambridge, Massachusetts, United States, Northern America, Americas · Business Development · Jul 24, 2026 Chief Technology Officer (Biotech)Cambridge, MA · C-Level · Jul 21, 2026 Recruiting New hires Director, ADC & DAC (Contract-to-Hire) Pinetree Therapeutics 26.07.13Cambridge, Massachusetts, United States, Northern America, Americas · Other · Jul 21, 2026

8 distinct openings shownExplore hiring signals →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
HTHarness TherapeuticsA private biotechnology company, headquartered in Cambridge-UK, focused on the development of a novel class of therapeutic RNAs	Babraham, United Kingdom	Operational	5	$35M	$90M
KIKimialysDeveloper of an analytical device intended to offer products based on innovative surface chemistry in the field of biosensors	Paris, France	Operational
SISideROSFocused on accelerated development of innovative small molecules targeting tumour cells metabolism in high-risk cancers	Paris, France	Closed
ANAntegenesGenetic tests for personalized cancer risk prevention	Tartu, Estonia	Operational
BPBrenus PharmaProducing the widest panel of tumor associated antigens and resistance markers with a chemical labeling enable to induce cell death by patients' immune system	Clermont-Ferrand, France	Operational
EBExeliom BiosciencesDeveloping single bacterial strain drug candidates to deliver first-in-class microbiome-based therapeutics	Dijon, France	Operational
MTModalis TherapeuticsEpigenetic gene modulation therapies for genetic disorders	Cambridge, United States	Operational
HPHcs PharmaA company specializing in cell imaging	Loos, France	Operational